))
Episode 25. Managing Acute Toxicities of CAR T-cell Therapy
Manage episode 367350833 series 3369804
İçerik Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff tarafından sağlanmıştır. Bölümler, grafikler ve podcast açıklamaları dahil tüm podcast içeriği doğrudan Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff veya podcast platform ortağı tarafından yüklenir ve sağlanır. Birinin telif hakkıyla korunan çalışmanızı izniniz olmadan kullandığını düşünüyorsanız burada https://tr.player.fm/legal özetlenen süreci takip edebilirsiniz.
In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.
Here are some of the key articles we discussed:
1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.
https://pubmed.ncbi.nlm.nih.gov/36989488/
2. CAR-HEMATOTOX score:
https://pubmed.ncbi.nlm.nih.gov/34166502/
3. “How I treat cytopenias after CAR T-cell therapy”.
https://pubmed.ncbi.nlm.nih.gov/36800563/
4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):
https://pubmed.ncbi.nlm.nih.gov/36906275/
5. ASTCT consensus grading for CRS and ICANS:
https://pubmed.ncbi.nlm.nih.gov/30592986/
6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:
https://pubmed.ncbi.nlm.nih.gov/35696759/
7. Modified EASIX score for predicting CRS and neurotoxicity:
47 bölüm
Paylaş
